A Phase 2, multicenter, open-label, long-term safety study of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201 and are candidates for continuous treatment for up to 52 weeks

Project: Research

Project Details

StatusActive
Effective start/end date19/10/23 → 20/10/25

Keywords

  • clinical trial
  • epilepsy
  • encephalopathy